Supernus Pharmaceuticals' projection of its FY24 total revenue to be below the market estimate could lead to negative investor sentiment and potentially decrease the stock price in the short term. This is because financial forecasts that do not meet or exceed market expectations often result in a negative perception of the company's future financial health and growth prospects.